Search

Displaying results 3891 - 3900 of 4188 in total
  1. Drug

    Mycophenolate mofetil

    go.drugbank.com/drugs/DB00688
    ApprovedInvestigational

    [A180826] In addition to the above uses, mycophenolate mofetil has also been studied for the treatment of nephritis and other complications of autoimmune diseases.

  2. Drug

    Insulin icodec

    go.drugbank.com/drugs/DB16693
    ApprovedInvestigational

    [L50763] It has also been approved in Japan and Australia.

  3. Drug

    Undecylenic acid

    go.drugbank.com/drugs/DB11117
    Approved

    Undecylenic acid was first isolated from the products of distillation of castor oil in 1877 via pyrolysis of ricinoleic acid, and has been polymerized for vinyl production [A32281].

  4. Drug

    RGX-181

    go.drugbank.com/drugs/DB17942
    Experimental

    RGX-181 consists of an adeno-associated virus serotype 9 (AAV9) vector designed to deliver the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1) gene.

  5. Drug

    LM-609

    go.drugbank.com/drugs/DB05787
    Experimental

    In addition to cancer, the protein has been implicated in bone destruction in rheumatoid arthritis and the inflammatory process in psoriasis.

  6. Drug

    VY-HTT01

    go.drugbank.com/drugs/DB16999
    Investigational

    VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression.

  7. Drug

    Saprisartan

    go.drugbank.com/drugs/DB01347
    Experimental

    The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan.

  8. Drug

    Sonepcizumab

    go.drugbank.com/drugs/DB06305
    Investigational

    S1P is the extracellular ligand for the G protein-coupled lysophospholipid receptor EDG-1 (endothelial differentiation gene-1).

  9. Drug

    Mitometh

    go.drugbank.com/drugs/DB12117
    Investigational

    Mitometh has been investigated for the treatment of Lung Neoplasms, Untreated Childhood Medulloblastoma, and Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor.

  10. Drug

    WNY0824

    go.drugbank.com/drugs/DB23606
    Experimental

    [A274253] It is a dual inhibitor of PLK-1 and BRET-4, which have both been found to be involved in CRPC via suppression of AR/MYC-mediated transcription. [A274258]